

FIG. 1.

Multiple Alignment:

30664188.0.99 VEGF-E	1	MHR LI FVYT LICANFC SCR DT SATPQSAS I KALRNANL RDES N HLT Y R D E T I Q X KG 1 - - M S L E G L L I L L T S A L A G Q E Q GT Q A E S N L S S K F Q F S S N K - - E Q N G V Q D P Q - H E R I I T V S T	60 54
30664188.0.99 VEGF-E	61 55	NG Y V Q S P R E P N S Y P R E N L L I T W R L H S - Q E N T R I Q L Y F D N Q F G L E A E N D I C R Y D F V E V E D I NG S I H S P R E P H T Y P R N T V L W R R L V A T E E N W W I Q L T F E D E R F G L E D P E D D I C K Y D F V E V E E P	119 114
30664188.0.99 VEGF-E	120 115	S E T S T I I R J R W C G H K E W P P R I K S R T N Q K I T F K S D D I F V A K P G E K I Y W S L L E D F Q P A A S S D G - T I I L J R W C G S G T W P G K Q I S K G N Q I R I R F V S D E E V F P S E P G F C I H W N I V M P - - - - - 179 165	
30664188.0.99 VEGF-E	180 166	E T N W E S V T S S I S G W S Y N S P S V T D P - T L I A D A L D K K I A E F D T V E D L K Y F N P E S W Q E D L I E N - - - - - Q F T E A V S - - - - - P S V L P P S A L P L D I L N N A I T A F S T L E D L I R Y L E P E R W Q L D L E D	238 214
30664188.0.99 VEGF-E	239 215	M Y L D T P R Y R S R S Y H D - R K S - K W D L D R I N D D A K R Y S C T P R N Y S W N I R E E L K L A N V V F F P R S L Y R P T W Q L I L E K A F V F R K S R V W D I N L I T E E V R L Y S C T P R N F S W S I R E E L K R T D T I E W P G S	296 274
30664188.0.99 VEGF-E	297 275	L L V Q R C G G N C G C G T V M W R S S T T N S G K T V K K Y H E V L Q F E P G H I K R R G R A K T M A L V D I Q L D H L L V K R C G G N C A C C L H N C N E Q E W P S K V T K K Y H E V L Q L R P - - - K T G V R G L H K S I T D V A L E H	356 331
30664188.0.99 VEGF-E	357 332	H E R C D C I C S S R P P R (SEQ ID NO:2) H E E C D C V R G S T G G (SEQ ID NO:28)	370 345

FIG. 2.



FIG. 3.




FIG. 4A



FIG. 4B




FIG. 5.




FIG. 6.

BrdU Proliferation NIH 3T3 5-24





FIG. 7.



30664188

Mock




FIG. 9.

Growth 5-15-00 NHost




FIG. 10.

FIG. 10A (without serum)




FIG. 11.




FIG. 12

*

hPDGF D	CTPRNYSVNI - REELKLANVVF - - FPRCLLVQRCGGNCACCGTVNWRSCTC
mPDGF D	CTPRNHSVNL - REELKLTNAVF - - FPRCLLVQRCGGNCACCGTVNWKSCTC
PDGF C	CTPRNFSVSI - REELKRTDTIF - - WPGCLLVKRCGGNCACCLHNCNECQC
PDGF B	CKTRTEVFEISRRLIDRTNANFLVWPPCVEQRCSG - - - CNNRNQCRP
PDGF A	CKTRTVIYEIPRSQVDPTSANFLIWPPCVEVKRCTG - - - CCNTSSVKCQP
hPDGF D	NS - - GKTVKKYHEVLQFEPGHIKRRGRAKTMALVDIQLDHHERCDC (SEQ ID NO:15)
mPDGF D	SS - - GKTVKKYHEVLKFEPGHFKRRGAKNMALVDIQLDHHERCDC (SEQ ID NO:16)
PDGF C	VP - - SKVTKKYHEVLQLRPKTGVRGLH - KSLTDVA - - LEHHEECDC (SEQ ID NO:17)
PDGF B	TQVQLRPVQVRKIEIVRKPIF - - - KKAT - VT - - LEDHLACKC (SEQ ID NO:18)
PDGF A	SRVHHRSVKVAKVEYVRKKPKL - - - KEVQ - VR - - LEEHLECAC (SEQ ID NO:19)

FIG. 13

Exon 1 → Exon 1
1 DGCAGGGGGGGCGGGGTCGGTCCCCGGAGCAGAACCCGGCTTTTCTTGGAGGACGGCTGTCTAGTGCTGATCCCA
81 AATG[]ACCGGCTCATCTTGCTCACACTTAATCTGCCAAACTTTGCAGCTGCGGACACTTCTGCAACCCCGAGA
M H R L I F V Y T L I C A N F C S C R D T S A T P Q S
161 GCGCATCCATCAAAGCTTGGCGAACGGCAACCTCAGGGAGATAGAGCAATCACCTCACAGACTTGTAACCGAAGAGAT
A S I K A L R N A N L R R D E S N H L T D L Y R R D
241 GAGACCACAGGTGAAAGGAAACGGGTAAGTGCAGAGTCCTAGATTGGAACAGCTACCCAGGAACCTGCTCTGAC
E T I Q V K G N G Y V Q S P R F P N S Y P R N L L L T
321 ATGGGGGTTCACTCTCAGGAGAACACGGATAACAGCTAGTGTGGACAAATCAGTTGGATTAGAGGAAGCAGAAAATG
U R L H S Q E N T P I Q L V F D N Q F G L E E A E N D
401 ATATCTGTAAGTATGATTTGGAAAGTATATCGAACAGCTACCTTATTAGAGGGACGATGTGGACAC
I C R Y D F V E V E D I S E T S T I I R G R W C G H
481 AANGAAGTTCTCCAAAGGATAAAATCAGAACGAAACAAATTAAATCACATTCAAGTCGGATGACTACTTGTGGCTAA
K E V P P R I K S R T N Q I K I T F K S D D Y F V A K
561 ACCTGGATTCAAGATTATTCTTGTGGAAAGATTCTTCAACCCGCAAGCTTCAGAGAACAACTGGGAATCTGTCA
P G F K I Y Y S L L E D F Q P A A A S E T N W E S V T
641 CAAGCTCTATTTCAGGGGTATCTATAATCTCCATCAAGGATCCCACACTCTGATTGGGATGCTCTGGACAAAAAA
S S I S G V S Y N S P S V T D P T L I A D A L D K K
721 ATTGGAGAATTGATACAGTGGAAAGATCTGTCAGTACTTCATGGCAAGAACAGATCTTGAGAATATGTA
I A E F D T V E D L L K Y F N P E S W Q E D L E N M Y
801 TCTGGACACCCCTCGGTATGGGAGGTATACCATGAGGAAGTCAATGGCTGACCTGGATAGGCTCAATGATGATG
L D T P R Y R G R S Y H D R K S K V D L D R L N D D A
881 CCAGGGTTACAGTTGCACTCCAGGAATTACTGGTCAATATAAGAGAACAGCTGAAAGTTGGCCAATGTTGCTTCTT
K R Y S C T P R N Y S V N I R E E L K L A N V V F F
961 CCACGTTGCTCTCGTGCAGGGCTGTGGAGGAAATTGTGGCTGTGGAACTGTCAACTGGAGGTCTGCACATGCAATT
P R C L L V Q R C G G N C G C G T V N W R S C T C N S
1041 AGGGAAAACCGTGAAGGAAAGTATCATGAGCTTACAGTTGGAGCTGGCACATCAAGAGGGTAGAGCTAACAGCCA
G K T V K K Y H E V L Q F E P G H I K R R G R A K T M
1121 TGGCTCTAGTTGACATCCAGTTGGATCACCATGAACGATGTGATTGATCTGCAAGAACACCTCGATAAGAGAAAT
A L V D I Q L D H H E R C D C I C S S R P P R (SEQ ID NO:20)
1201 GTGCACATCTTACATTAAGGCTGAAAGAACCTTCTGGTTAAGGGGGTGAGATAAGAGAACCTTCTTCTACAGCAAC
1281 AAACCTTACTACTAGCCTGCAATGCAATGAAACACAAAGTGGTTGTGAGTCAGCCTTGCTTGTAAATGCCATGGCAAGT
1361 AGAAAGGTATATCATCAACTCTATAACCTAAGAATATAGGATTGCAATTAAATAATAGTGTGTTGAGGTTATATATGCAACAA
1441 ACACACACAGAAATATATTCTATGCTATGTGTATATAGATCAAAATGTTTTGGTATATATAACCAAGGTACACCAGAG
1521 CTTACATATGTTGAGTTAGACTCTTAAATGCTGGCAAAATAAGGGATGGTCAAATATATGAAACATGCTTTAGAA
1601 AATTAGGAGATAAAATTATTTAAATTGAAACACAAACATTGAAATCTGCTCTTAAAGAAAGCATCTTGT
1681 ATATTAAGGAGATGAGGCTTCTTACATATACATCTTAGTGC (SEQ ID NO:21)

FIG. 14




FIG. 15

V5 6HIS

A. 27 KDa 
GRSYHDRSKVLDRL (SEQ ID NO:22)
GRSYHDRSKVD..... (SEQ ID NO:23)

B. 16 KDa 
GRSYHDRSKVLDRL (SEQ ID NO:24)
GRSYHDRSKVD..... (SEQ ID NO:25)

C. 6 KDa 
V5 6HIS
RGRAKTMALVDIQLDHHE (SEQ ID NO:26)
RGRAKTMALVDIQ..... (SEQ ID NO:27)

FIG. 16




FIG. 17




FIG. 18

Competition of 30664188 p30 or PDGF BB by 30664188 p85




FIG. 19




FIG. 20

CCD1070 Growth: Competition by Anti-Receptor Antibodies




FIG. 21

Smooth Muscle Treated with p30 30664188, PDGF AA, PDGF BB




FIG. 22




FIG. 23




FIG. 24

Neutralization of 30664188 by Fully Human Polyclonal Ab




Fig. 25.

Panel A




Fig. 25 (cont.)

Panel B




FIG. 26.

BrdU CCD1070 Soluble Alpha PDGFR Competition




FIG. 27A




FIG. 27B




FIG. 28

32D Alpha PDGFR Proliferation




FIG. 29A




FIG. 29B




FIG. 29C




FIG. 29D

